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Major attention was first focused on the problem of
acute hemolytic anemia in the early 1950's, during
the Korean War. Large numbers of American Negroes
stationed in Korea developed this anemia after taking
primaquine for treatment or prophylaxis of malaria.
A study group was formed in Chicago under the direction of Alving; it was this group of investigators
who contributed much of the early information which
has led to our understanding of this type of anemia
(Dern, et al, 1954; Dern, Beutler and Alving, 1954;
Beutler, Dern and Alving, 1954). This also resulted in
an upsurge of interest in red cell metabolism, and led
to many of the advances we are hearing about in this
lecture series.

usual hematologic studies were normal and were of
no help in detecting the susceptible individual. The
first significant clue came when Heinz bodies were
noted on supravital staining of the peripheral blood
smear during the acute hemolytic episode. This gave
rise to the first in vitro test for detecting primaq uinesensitive individuals, the Heinz body test devised by
Beutler (Beutler, Dern and Alving, 1955). In this test
blood is incubated with the oxidant drug, acetylphenylhydrazine, and then observed for the presence of Heinz
bodies. Fig 2 shows that the red cells from a susceptible individual, on the left, have many small Heinz
bodies; while normal red cells, on the right, have one
or two large Heinz bodies.

Clinical Course
The clinical course of primaquine-induced hemolysis is illustrated in Fig 1. Acute intravascluar hemolysis occurs two to four days after exposure to the drug,
and is accompanied by hemoglobinuria. The hematocrit continues to fall for seven to 12 days and approximately 30 to 50 percent of the red cell mass is destroyed (Dern et al, 1954; Dern, Beutler and Alving,
1954). As the reticulocyte response reaches its peak
in around ten to 12 days, the hematocrit begins to rise
again and gradually returns to normal levels in four to
five weeks, even though primaquine is continued.
Radioiron red cell labeling studies have shown that it
is the older population of red cells that is most susceptible to primaquine hemolysis while young erythrocytes
are relatively resistant (Beutler, Dern and Alving,
1954). However, if the dosage of primaquine is increased sufficiently even the younger cells are hemolyzed.
At the time of the Korean War, the only way to
detect a primaquine-sensitive soldier was to challenge
him with the drug, which was not without danger. The

Mechanism of the Anemia

* Presented at the 23rd Annual Stoneburner Lecture
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The formation of Heinz bodies is of major importance in the pathogenesis of this type of hemolytic
anemia. The importance of deformability of the red
cell as it travels through the microcirculation has been
stressed throughout this lecture series. Heinz bodies,
which represent precipitated denatured hemoglobin,
are rigid bodies which hamper pliability of the red
cell and interfere with its ability to traverse the microcirculation, particularly in the spleen. Rifkind (1965 ;
1966) has demonstrated this very nicely with electron
microscopy of red cells containing Heinz bodies in the
spleen. Fig 3 shows several red cells with Heinz bodies.
One red cell is completely devoid of hemoglobin except for the Heinz bodies which are firmly attached to
the red cell membrane. In Fig 4 a red cell is shown
going from a splenic cord into a sinus. It is apparent
that the Heinz body in the tail will prevent either the
entire red cell or a portion of it from making it through.
Although the Heinz body test was useful in detecting
primaquine-sensitive individuals, it shed no light on
the underlying biochemical defect. The first biochemical lead was the observation that red cell reduced
glutathione (GSH) was lower in affected individuals
than in normals. This difference was slight when fresh
blood was used, but when blood was incubated for
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Fig. 1-Clinical course in primaquine-induced hemolytic anemia. (From Alving AS, Johnson CE, Tarlov AR: Mitigation of the
haemolytic effect of primaquine and enhancement of its action against exoerythrocytic forms of the chesson strain of plasmodium
by intermittent regimens of drug administration. Bull WHO 22 : 625, 1960. Reprinted with permission.)
two hours with acetylphenylhydrazine there was a
marked fall in GSH levels in primaquine-sensitive red
cells with nearly no fall in normal cells (Beutler,
1957). (Fig 5) This formed the basis for the glutathione stability test for detecting susceptible individuals.
This observation focused attention on erythrocyte
glutathione metabolism and eventually led to the delineation of the basic red cell defect. Glutathione re-

ductase was studied first. When this proved to be normal, glucose-6-phosphate dehydrogenase ( G6PD) was
assayed and found to be deficient (Carson, et al,
1956) .
The importance of the G6PD-glutathione system in
protecting the red cell from oxidative injury can be
summarized in a series of interrelated reactions (Table
l) .

Table 1
Interrelated Reactions of the G6PD-glutathione System in Protecting the Red Cell from Oxidative Injury
gl utathione
I . Red Cell + oxidant

----~

H20 2

3. GSSG + NADPH +

H+----~

2GSH + NADP +

reductase
glutathione
2. H20 2 + 2GSH

G-6-P
2H,O + GSSG 4. G-6-P + NADP +

peroxidase

6-PG + NADPH + H +
dehyi;lrogenase

/
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When the red cell is subjected to oxidative stress
through exposure to some drug or infectious agent,
hydrogen peroxide is generated. Although the erythrocyte is rich in catalase, which decomposes H,O,, glutathione peroxidase seems to be more important in the
reduction of H,0 2. An hereditary deficiency in catalase
(Aebi, Heiniger arid Suter, 1963) is not associated
with hemolytic anemia while a deficiency of glutathione peroxidase is (Steinberg, Brauer and Necheles,
1970).
For glutathione peroxidase to remain effective in reducing H,O, to H,O a continuous supply of GSH must
be available. This is accomplished by the reduction of
GSSG to GSH by glutathione reductase, which in turn
requires NADPH as a cofactor. A deficiency of glutathione peroxidase, glutathione reductase or glucose-6phosphate dehydrogenase, or the inability to synthesize
glutathione all lead to defective reduction of H 20,
and hemolytic anemia. When H,02 accumulates, hemoglobin is irreversibly oxidized and precipitated as
Heinz bodies (Mills and Randall, 1958; Cohen and
Hochstein, 1961).

Tests to Detect G-6-PD Deficiency
We have mentioned the Heinz body and glutathione
instability tests as methods to detect G6PD deficiency,
but they are somewhat cumbersome, indicating a need
for simple screening tests for large populations. We
have found the methemoglobin reduction test (Brewer,
Tarlov and Alving, 1960) to be simple and reliable.
This test is based on the fact that there are two methemoglobin reductases in the red cell-one using
NADH as a cofactor, and the other using NADPH
which is derived from the G6PD reaction in the pentose phosphate pathway. Blood is incubated with sodium nitrate which oxidizes oxyhemoglobin to methemoglobin. Methylene blue is also added to stimulate
the pentose shunt which leads to more efficient methemoglobin reduction. When there is G6PD deficiency
the shunt is not stimulated, NADPH is not generated,
and methemoglobin is not reduced properly. After
two hours the brown color of methemoglobin remains,
rather than the red color of oxyhemoglobin which is
present after two hours incubation of normal blood. :
This test is simple to perform, requires only a few·

Fig. 2- Heinz body formation after incubation with acetylphenylhydrazine. Primaquine-sensitive red cells on the left, normal red
cells on the right. (From Beutler E, Dern RJ, Alving AS: The hemolytic effect of primaquine. VI. An in vitro test for sensitivity
of erythrocytes to primaquine. J Lab Clin Med 45: 43, 1955. Reprinted with permission.)
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Fig. 3- Electron micrograph of red cells containing Heinz bodies in the spleen. Cell 3 is devoid of hemoglobin except for Heinz
bodies attached to the membrane. (From Rifkind RA:' Heinz body anemia: an ultrastructural study. II. Red cell sequestration
and destruction. Blood 26: 438, 1965. Reprinted with permission.)

common reagents, and can be read visually. However,
it often gives equivocal results if carried out during an
acute hemolytic episode, and is poor in picking up
female heterozygotes.
The cyanide-ascorbate test of Jacob and Jandl
( 1966) is another simple screening test which can be
read visually. This test has an advantage in that it is
usually positive in the face of acute hemolysis and will
usually detect female heterozygotes. The ascorbic
acid causes generation of H.O,, which stresses the
system described previously; the cyanide inhibits
catalase. Thus, not only a deficiency in G6PD but a
deficiency in the other enzymatic steps in the system
also gives a positive test.
A young man whom we worked up recently for an
hereditary hemolytic anemia provided a good example
of the usefulness of this test. The methemoglobin reduction test was negative for G6PD deficiency; the
cyanide-ascorbate test was positive, which immediately
focused attention on the glutathione system. Enzyme
assays for G6PD, glutathione reductase, and glutathione peroxidase were all normal or increased; but

the level of GSH was found to be only ten percent
of normal. Further studies showed that the patient had
a deficiency of glutathione synthetase, which was responsible for his hemolytic anemia. The patient was
homozygous for the deficiency, while his parents were
heterozygous and had a lesser degree of red cell glutathione synthetase deficiency (Mohler et al, 1970).
Although several families with this type of enzyme
deficiency have been reported in Europe, this was the
first such report in America. For the reasons enumerated, we now believe that the cyanide-ascorbate test
is the most satisfactory screening test.
Variants of G6PD Deficiency

Although in the United States G6PD deficiency is
seen primarily in the Negro (ten to 13 percent of
Negro males) , the deficiency occurs in many ethnic
groups and over 50 mutations have now been described
(Carson and Frischer, 1966; Kirkman, Kidson and
Kennedy, 1968).
The enzyme has been purified and found to have a
molecular weight of approximately 240,000 consisting
45
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Fig. 4-Electron micrograph of a red cell passing from a splenic cord, below, to a splenic sinus above. The tail of the cell contains several large Heinz bodies which are impeding its progress. (From Rifkind RA: Heinz body anemia: an ultrastructural study.
II. Red cell sequestration and destruction. Blood 26: 436, 1965. Reprinted with permission.)
of six peptide subunits weighing 40,000. There are
two major electrophoretic patterns which are designated A and B. Table 2 shows which electrophoretic
type occurs in various population groups. Normal
Caucasians have only type B, while 82 percent of normal Negroes have type B and 18 percent have type A.
Most Caucasians have G6PD deficiency type B, while
in the Negro the common deficiency type is A and
rarely B.
Yoshida (1968) and his colleagues have shown that
the only difference between types A and B G6PD is
that type A has aspartic acid while type B has asparagine. A great many biochemical comparisons in terms
of enzyme kinetics have been made between normal
and defic;ient type A in Negroes. The only difference
which has been found is that the enzyme is degraded
more rapidly in the deficient erythrocyte than in the
normal (Yoshida, 1968). This explains why older red
cells are more susceptible to oxidant stress than
younger cells, since the G6PD content falls rapidly as
46

the red cell ages. This also explains why it is only the
mature red cell which shows a deficiency of G6PD in
the Negro, as white cells have a short life span.
However, in G6PD deficiency in Caucasians from
the Mediterranean, type B, the deficiency is noted in
leukocytes as well as erythrocytes. Also, a kinetic difference has been observed when comparing the normal and deficient enzyme; the latter has a weaker affinity for its substrate, glucose-6-phosphate (Yoshida,
1968).
Fig 6 shows the world distribution of G6PD deficiency. It has been estimated that over 100 million people have this enzyme deficiency (Carson and Frischer,
1966; Beutler, 1966). Since the distribution follows
mainly tropical areas where there is a high incidence
of malaria, it has been proposed that the enzyme deficiency affords some protection against infection with
the malarial parasite and accounts fer its increased
prevalence in such areas. However, malnutrition and
other diseases with a similar geographic distribution,
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Fig 5-Content of GSH in primaquine-sensitive and normal red cells before and after incubation with acetylphenylhydrazine. (From Beutler E: The glutathione instability of drug-sensitive red cells. J Lab Clin Med 49: 89,
1957. Reprinted with permission.)

TABLE 2
Variants of Glucose-6-Phosphate Dehydrogenase
Amino Atid
Electrophoretic
Population
Type
Substitution
Normal Caucasian
Normal Negro
Deficient Caucasian
Mediterranean
Chinese
Deficient Negro
Common
Rare

B+
B+ (823 )
A+ (18 3 )

Aspartic acid for
asparagine

BBAB-

such as plague, might also play a role (Carson and
Frischer, 1966).
Negroes and Caucasians from the Mediterranean
area with G6PD deficiency are not anemic and do not
display overt hemolysis unless exposed to the oxidant
stress of some drug or infection. In contrast, Caucasians from Northern Europe and some other parts of
the world have a congenital nonspherocytic hemolytic
anemia secondary to their G6PD deficiency. Less than
one percent of Caucasians of Northern European origin have this deficiency. The anemia is usually fairly
mild, with hematocrits in the mid 30's, and becomes
much worse upon exposure to oxidant drugs.

Fig 7 shows a family which we have reported (Mohler and Crockett, 1964) in which two first cousins were
affected. The gentic transmission here, as in all cases
of G6PD deficiency, is sex linked; the hemizygous
sons show the full effect of the deficiency, and the
heterozygous mothers show variable expression. In
our two patients there was no measurable red cell
G6PD activity and the mothers had borderline low
values.
Fig 8 shows a comparison of G6PD levels in various
groups. In our laboratory normal G6PD activity ranges
from four to seven units. The patients with higher than
normal levels had a variety of hemolytic anemias with
reticulocytosis, the increased number of young red
cells accounting for the elevated G6PD activity. The
second column shows deficient Negroes who had about
ten percent of normal activity. The last column shows
three Caucasians with no measurable activity, and
includes the two patients shown in Fig 7 plus a man of
Turkish ancestry. The values in the top part of that
column represent the relatives of the two cousins depicted in Fig 7, and again illustrate the borderline
levels of the mothers.
Causes of Acute Hemolytic Episodes in a G6PD
Deficient Individual
Table 3 lists some of the most common oxidant
drugs; more complete lists are also available (Carson
and Frischer, 1966; Beutler, 1966). Most of these
drugs are aromatic amines; all of them act as electron
carriers, hence having the ability to generate H.O. and
act as oxidants. Some are potent oxidants, such as the
sulfonamides and nitrofurans. Others, such as aspirin
and chloramphenicol, are relatively weak and cause
hemolysis only in Caucasians with very low G6PD
levels or when they are used in high dosages.
It is well known that a variety of drugs produce
acute hemolysis in a G6PD deficient patient, but it has
not been sufficiently emphasized that infections alone
also cause hemolysis. Burka and his associates (Burka,
Weaver and Marks, 1966; Burka, 1969), reviewing a
large number of hemolytic episodes in G6PD deficient
patients seen at Columbia-Presbyterian Hospital, found
that infections alone were a more common cause of
hemolysis than drugs alone. Acute hemolytic episodes
occurred after bacterial pneumonia and a variety of
viral infections, particularly viral hepatitis.
They also pointed out in their study that many
women had hemolytic episodes. Approximately two
percent of Negro women are homozygous for G6PD
deficiency and would be expected to react to oxidant
stress; but heterozygous female carriers, or about 20
percent of Negro women, were not thought to be
susceptible. This study pointed out that there is enough
variation in enzyme levels in female heterozygotes, in
keeping with the Lyon hypothesis, that a significant
47

GLUCOSE-6-PHOSPHATE DEHYDROGENASE DEFICIENCY

number will hemolyze when exposed to the oxidant
stress of drugs or infection.
In summary, G6PD deficiency should be suspected
and tested for not only in Negro men who are taking
oxidant drugs, but also in Negro women and during
acute infections whether drugs are used or not.
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TABLE 3
Some Common Drugs which Produce Hemolysis of G6PD
Deficient Red Cells
Sulfonamides
Sulfamethoxypridazine (Kynex @, Midice @I)
Sulfisoxazole (Gantrisin @)
Salicylazosulfapyridine (Azulfidine @)
N itrofurans
Nitrofurantoin (Furadantin ®)
Furaltadone (Altafur ®)
Nitrofurazone (Furacin ®)
Analgesics
Acetylsalicylic acid
Acetanilide
Acetophenetidin (Phenacetin)
Diuretics
Thiazides (Diuril ®, Hydrodiuril @)
Acetazolamide (Diamox®)
Hypoglycemic Agents
Tolbutamide (Orinase @)
Chlorpropamide (Diabinese @)
Miscellaneous
Chloramphenicol (Chloromycetin®)
Para-Aminosalicylic Acid (PAS)
Vitamin K (Hykinone@)
Naphthalene (Moth Balls)
Fava Beans
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~ DIED AT AGE 10 YRS. OF UNKNOWN TYPE OF BLOOD DISORDER
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F ig 7-Pedigree of a Caucasian family with erythrocyte
G6PD deficiency. (From Mohler DH, Crockett CL:
Hereditary hemolytic disease secondary to glucose-6phosphate dehydrogenase deficiency: report of three cases
with special emphasis on ATP metabolism. Blood 23: 429,
1964. Reprinted with permission.)
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Fig 8-Glucose-6-phosphate dehydrogenase activity of red
cells from normal subjects, and from enzyme deficient
Negro and Caucasian individuals.
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